Venture Leaders Medtech 2024: 10 startups selected for Boston Roadshow

The new team once again demonstrates Switzerland's leading role in medtech innovation. Venture Leaders Medtech is organized by Venturelab and Swissnex Boston and New York and supported by EPFL, ETH Zurich, Hansjörg Wyss, Health Innovation Hub Aargau, Kellerhals Carrard, Canton of Vaud, Canton of Zurich and Vischer.

The selected startups will represent Swiss medtech innovations in the United States for one week. During the week-long roadshow, the 10 Venture Leaders will meet investors in the US and interact with medtech industry executives and experts. "We've been bringing the best Swiss startups to Boston for 18 years, and it's a testament to the quality of innovation and startups that have been part of this trip," said Stefan Steiner, co-director of Venturelab. "I look forward to attending again this year and supporting the team in its international expansion."

To select the 10 Venture Leaders Medtech 2024, a jury of professional investors and medtech experts reviewed 60 applications. The 10 selected startups represent an exceptional group of companies that are tackling global healthcare challenges in various areas, such as increasing the availability of organ transplants, improving orthopedic aftercare with implantable biosensors, optimizing fertility treatments or using AI to transform complex disease data into actionable insights for precision medicine.

Boston is one of the world's leading centers for life sciences and the ideal springboard for ambitious startups on their path to global expansion. By building a strong network, entrepreneurs can accelerate their international growth. "Venture Leaders Medtech in Boston has fostered our industrial and clinical contacts in the US in an unprecedented way and helped me make strong connections with other Swiss CEOs - which is just as important for me as building business relationships with future customers and partners," emphasized Siew-Veena Sahi, CEO of Testmate Health and Venture Leader Medtech 2023.

These are the Venture Leaders Medtech 2024 representatives:

Apersys | Zurich | www.apersys.com

Apersys has made it its mission to save more patients in need of organ transplants. Apersys' perfusion platform technology lays the foundation for increasing the number of transplantable organs and promotes translational research.

Aseptuva | Bern | www.aseptuva.com

Aseptuva aims to prevent secondary infections in hospitals with patented remote UVC technology. Aseptuva's medical devices disinfect catheter inlets in a safe, targeted and hands-free manner, saving the lives of thousands of patients, reducing the burden on healthcare staff and combating the increase in antimicrobial resistance.

Bios Medical | Davos | www.biosmedical.care

Bios Medical is revolutionizing orthopaedic aftercare with implantable biosensors. The medtech start-up monitors the healing process remotely around the clock to enable personalized care plans and support the patient.

Calico BIosystems | Crissier | www.calicobiosystems.com

Calico Biosystems is an experimental and digital platform that tests the efficacy of cancer drugs on patient tumors and accelerates their clinical development by predicting life-changing drugs.

Citus | Dübendorf | www.citus-ag.com

Citus offers an evidence-based skin assessment. Using objective, non-invasive measurements and a comprehensive database, Citus enables the severity of a skin condition to be classified. In combination with AI, it enables predictive care and early intervention.

Impli | Epalinges | www.impli.org

Impli aims to revolutionize healthcare with a high-precision hormone monitoring platform. It starts with the infertility market, which affects 186 million people worldwide, and improves IVF treatments through precise hormone measurements.

Metadvice | Saint-Sulpice | www.metadvice.com  

Metadvice AI distills complex treatment and outcomes data into actionable insights for clinicians and patients. The clinical knowledge engine draws data from a network of physicians to optimize precision medicine.       

Mynerva | Zurich | www.mynervamedical.com   

Mynerva has developed Leia, a breakthrough medical device that uses a combination of AI and non-invasive neurostimulation to reduce falls and chronic pain in patients with diabetic neuropathy.            

OncoSwab | Courroux | www.oncoswab.com

OncoSwab aims to revolutionize the detection of lung cancer with a non-invasive nasal test that enables early diagnosis for life-saving interventions.

OneTwenty | Zurich | https://onetwenty.ai/

OneTwenty improves diabetes management with groundbreaking AI-driven algorithms. It offers the first safe solution that autonomously controls human metabolism to help people with diabetes.

Participation in the presentation of the team and the online pitch session on September 18, 2024.  

Source: www.venture-leaders.ch